Contact UsCareers
Top bar
WHO WE ARE
  • OUR MISSION
  • MEET OUR TEAM
    •  PIPELINE
  • OUR APPROACH
  • GAMMA SECRETASE INHIBITORS (GSIs)
  • INVESTIGATIONAL THERAPIES: AL101 & AL102
    •  CLINICAL TRIALS
  • CLINICAL PRIVACY NOTICE
    • MEDICAL PROFESSIONALS PATIENTS & CAREGIVERS
  • SCIENCE EXPLAINED
  • PARTICIPATING IN CLINICAL TRIALS
  • EXPANDED ACCESS POLICY
  • PATIENT RESOURCES
    •  INVESTORS & MEDIA
  • NEWS RELEASES
  • EVENTS & PRESENTATIONS
  • FINANCIAL INFORMATION
  • STOCK INFORMATION
  • CORPORATE GOVERNANCE
  • RESOURCES
    •
    - Presented N ew P ositive I nterim D ata from 4mg C ohort of Phase 2 ACCURACY S tudy of AL101 for the T reatment of R/M ACC at European Society for Medical Oncology 2020 - - Trial In Progress Poster of Phase 2 TENACITY Study of AL101 Monotherapy in Patients w ith Notch-activated Triple-Negative